| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,397,746 ) |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK067536 | Role of IGF-1 and insulin receptors beta-cell survival | 001 | 18 | NIH | 11/15/2024 | $587,021 |
| | 2025 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 000 | 4 | NIH | 11/15/2024 | $811,054 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 000 | 2 | NIH | 11/13/2024 | $0 |
| | 2025 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 000 | 8 | NIH | 11/15/2024 | $0 |
| | 2025 | 2022 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK067536 | Role of IGF-1 and insulin receptors beta-cell survival | 000 | 17 | NIH | 11/14/2024 | $0 |
| | 2025 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK112153 | Feeding Drives HSF1 Transcriptional Programs Required for Global Protein Synthesis | 000 | 4 | NIH | 10/18/2024 | -$329 |
|
| Issue Date FY: 2024 ( Subtotal = $24,603,092 ) (Continued on the next page) |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 001 | 8 | NIH | 8/16/2024 | $517,097 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129850 | Gut microbial fermentation products of muscle-derived lactate as mediators of exercise and metabolism | 001 | 3 | NIH | 5/3/2024 | $37,349 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK131061 | Causal connections between axon guidance proteins and early progressive kidney function decline in diabetes | 000 | 3 | NIH | 6/5/2024 | $651,221 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132469 | Transcriptional and epigenetic regulation of thermogenic adipocyte program | 001 | 3 | NIH | 5/20/2024 | $36,835 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK106193 | Paternal Contributions to Metabolic Disease in Offspring: Environment, Epigenetics, and Sperm | 000 | 8 | NIH | 5/20/2024 | $695,275 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK082659 | Developmental genes, miRNAs and adipose tissue | 002 | 16 | NIH | 5/20/2024 | $0 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129850 | Gut microbial fermentation products of muscle-derived lactate as mediators of exercise and metabolism | 000 | 3 | NIH | 3/22/2024 | $560,231 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK082659 | Developmental genes, miRNAs and adipose tissue | 001 | 16 | NIH | 5/8/2024 | $670,261 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK137511 | Lipotoxicity and Maintenance of Metabolic Health | 000 | 2 | NIH | 5/7/2024 | $573,863 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132535 | Elucidating and targeting beta-cell senescence and its SASP | 000 | 3 | NIH | 5/7/2024 | $410,400 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK031036 | Insulin Receptor Structure and Turnover | 001 | 43 | NIH | 5/2/2024 | $39,228 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132469 | Transcriptional and epigenetic regulation of thermogenic adipocyte program | 000 | 3 | NIH | 4/2/2024 | $552,530 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K23DK137024 | Development of an intervention to target diabetes device use through an identity framework: ACCPTech (Adapt and Commit to CGM and Pump Technology) | 000 | 1 | NIH | 3/21/2024 | $190,284 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 000 | 2 | NIH | 3/11/2024 | $755,026 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK031036 | Insulin Receptor Structure and Turnover | 000 | 43 | NIH | 2/23/2024 | $588,433 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 000 | 7 | NIH | 2/13/2024 | $37,175 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK101043 | Exercise Regulation of Glucose Homeostasis | 000 | 26 | NIH | 2/21/2024 | $641,262 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK123459 | Understanding the role of the Complement Proteome in progressive Diabetic Kidney Disease | 000 | 5 | NIH | 5/16/2024 | $351,902 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK120445 | Functional Validation of Gene Modifications that Protect Beta Cells against Autoimmunity Identified by Genome-Wide CRISPR Cas9 Screening | 001 | 6 | NIH | 5/3/2024 | $25,350 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK140790 | Identifying Targets for Preventing Neurocognitive Complications in Youth with T1D | 000 | 1 | NIH | 8/22/2024 | $320,972 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | F99AG088573 | Insulin regulates aging-associated genes through chromatin topology | 001 | 1 | NIH | 8/26/2024 | $0 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK120445 | Functional Validation of Gene Modifications that Protect Beta Cells against Autoimmunity Identified by Genome-Wide CRISPR Cas9 Screening | 000 | 6 | NIH | 2/28/2024 | $380,250 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | F99AG088573 | Insulin regulates aging-associated genes through chromatin topology | 000 | 1 | NIH | 8/26/2024 | $37,463 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R25DK140752 | Joslin-BIDMC Postbac Program in Diabetes and Metabolism | 000 | 1 | NIH | 8/30/2024 | $392,258 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K99DK140526 | Pancreatic beta-cell glucose toxicity and mRNA translation | 000 | 1 | NIH | 7/26/2024 | $91,500 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129479 | Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults with T1D | 001 | 4 | NIH | 7/31/2024 | $646,831 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129479 | Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults with T1D | 002 | 4 | NIH | 8/1/2024 | $119,527 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK137518 | Glucagon Pump Therapy for Post-Bariatric Hypoglycemia: Merging Physiology and Engineering | 001 | 2 | NIH | 7/30/2024 | $690,723 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK138605 | Translational Programming of Beta-cells in Response to Glucose Toxicity | 000 | 1 | NIH | 8/1/2024 | $724,053 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK128429 | Alterations in Post-Receptor Insulin Signaling in Diabetes and Insulin Resistance | 000 | 4 | NIH | 6/28/2024 | $568,937 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01AG054215 | Homeostasis functions of SKN-1A/Nrf1 | 000 | 7 | NIH | 6/25/2024 | $525,247 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01EY026080 | Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration | 000 | 7 | NIH | 1/16/2024 | $471,383 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 000 | 6 | NIH | 7/23/2024 | $41,667 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 000 | 6 | NIH | 7/23/2024 | $34,285 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 000 | 6 | NIH | 7/23/2024 | $94,048 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK102898 | Fibroblast Growth Factor and Energy Metabolism | 000 | 9 | NIH | 4/5/2024 | $493,810 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK102898 | Fibroblast Growth Factor and Energy Metabolism | 001 | 9 | NIH | 5/20/2024 | $32,922 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 003 | 3 | NIH | 5/3/2024 | $0 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | P30DK036836 | Diabetes Research Center | 000 | 38 | NIH | 6/17/2024 | $1,706,072 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 000 | 3 | NIH | 11/13/2023 | $700,759 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 001 | 3 | NIH | 11/17/2023 | $77,861 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K99DK135927 | Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetes | 000 | 2 | NIH | 5/1/2024 | $90,000 |
|
